Etanercept - TNF receptor and IgG1 Fc fusion protein: Is it different from other TNF blockers?

Expert Opinion on Biological Therapy

Volumn 14, Issue 5, 2014, Pages 569-572

  Marotte, Hubert ^a   Cimaz, Rolando ^b  

^a HÔPITAL NORD   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Efficacy; Etanercept; Side effect; TNF blockers

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; HYBRID PROTEIN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

DRUG EFFICACY; DRUG SAFETY; GRANULOMATOSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; IRIDOCYCLITIS; MAINTENANCE THERAPY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; SARCOIDOSIS; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY;

ANTIBODIES, NEUTRALIZING; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898712576     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.896334     Document Type: Review

References (24)

1. Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 1988;53:45-53
2. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-Tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: Comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:1248-57
3. Furst DE, Weisman M, Paulus HE, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): Results of a dose-finding study in rheumatoid arthritis. J Rheumatol 2003;30:2123-6
4. Furst DE, Fleischmann R, Kopp E, et al. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. J Rheumatol 2005;32:2303-10
5. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: Structure and function. Trends Cell Biol 1995;5:392-9
6. Horton S, Walsh C, Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2012;12:235-49
7. Rigby WF. Drug insight: Different mechanisms of action of tumor necrosis factor antagonists-passive-Aggressive behavior? Nat Clin Pract Rheumatol 2007;3:227-33
8. Marotte H, Pallot-Prades B, Grange L, et al. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 2007;9:R61
9. Nystad TW, Furnes O, Havelin LI, et al. Hip replacement surgery in patients with ankylosing spondylitis. Ann Rheum Dis 2013. [Epub ahead of print]
10. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-Tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: Is it really a paradoxical side effect? Clin Exp Rheumatol 2012;30:700-6
11. Wendling D, Prati C. Paradoxical effects of anti-TNF-Alpha agents in inflammatory diseases. Expert Rev Clin Immunol 2014;10:159-69
12. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35
13. Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during antitumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10
14. Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50
15. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24
16. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebocontrolled trial. Gastroenterology 2001;121:1088-94
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9
18. Derer S, Till A, Haesler R, et al. mTNF reverse signalling induced by TNFalpha antagonists involves a GDF-1 dependent pathway: Implications for Crohn's disease. Gut 2013;62:376-86
19. Daien CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009;48:883-6
20. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
21. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8
22. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-Tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94
23. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78
24. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-Tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008;67:1229-34